Abstract
Cardiotoxicity of First-Line Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
Highlights
The main goal of chemotherapy is to destroy tumour cells at the maximum with minimal damage to healthy tissue, which is sometimes difficult to achieve due to the non-selectivity of chemotherapeutics
Cardiotoxicity become important in the past several years, as significant progress has been made in both, early diagnosis and the use of increasingly advanced antitumor drugs
The aim of this study was to establish the frequency of cardiotoxicity in the patients treated with the first-line chemotherapy with and without previous cardiovascular diseases
Summary
The main goal of chemotherapy is to destroy tumour cells at the maximum with minimal damage to healthy tissue, which is sometimes difficult to achieve due to the non-selectivity of chemotherapeutics. Cardiotoxicity was first observed in 1967 in children with leukaemia treated with doxorubicin, and it was more significant in 2009 when the International Association for Cardiology in Milan was established. The appearance mechanism may be type I or so-called anthracycline cardiotoxicity and type II or cardiotoxicity occurring in the application of biological or target therapy (e.g. trastuzumab) (Table 1) [1,2]. The main goal of chemotherapy is to destroy tumor cells at the maximum with minimal damage to healthy tissue, which is sometimes difficult to achieve due to the non-selectivity of chemotherapeutics. The aim of this study was to establish the frequency of cardiotoxicity in the patients treated with the first-line chemotherapy (gemcitabine and cisplatin vs paclitaxel and carboplatin)
Sign-in/Register to view highlights & summary 
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call